Four dividend-paying biopharmaceutical investments to buy purchase use genetics to produce growth and income amid the pandemic.
The four dividend-paying biopharmaceutical investments to purchase that use genetics include two biopharmaceutical industry giants that have been building their genomic capabilities in recent years, as well as two exchange-traded funds that offer some exposure to the sector and hold enough traditional pharmaceutical stocks to provide investors a modest dividend yield. I am among those who are hoping and praying that genetic research breakthroughs one day may provide long-sought treatments for muscular dystrophy, amyotrophic lateral sclerosis (ALS) and other diseases.
“Biotechnology stocks have been doing well recently, and that’s likely to continue,” said Bob Carlson, leader of the Retirement Watch investment newsletter. “Companies continue to announce breakthroughs, and a number of biotech companies are going public.”
Four Dividend-paying Biopharmaceutical Investments to Purchase Use Promising Genomic Medicine
However, the favorite genomic medicine stocks of Woods are focused on growth and do not pay dividends.
To read the rest of the column, please click here.
Paul Dykewicz, www.pauldykewicz.com, is an accomplished, award-winning journalist who has written for Dow Jones, the Wall Street Journal, Investor’s Business Daily, USA Today, the Journal of Commerce, Seeking Alpha, GuruFocus and other publications and websites. Paul, who can be followed on Twitter @PaulDykewicz, is the editor of StockInvestor.com and DividendInvestor.com, a writer for both websites and a columnist. He further is editorial director of Eagle Financial Publications in Washington, D.C., where he edits monthly investment newsletters, time-sensitive trading alerts, free e-letters and other investment reports. Paul previously served as business editor of Baltimore’s Daily Record newspaper. Paul also is the author of an inspirational book, “Holy Smokes! Golden Guidance from Notre Dame’s Championship Chaplain,” with a foreword by former national championship-winning football coach Lou Holtz. The book is great as a gift and is endorsed by Joe Montana, Joe Theismann, Ara Parseghian, “Rocket” Ismail, Reggie Brooks, Dick Vitale and many others.